JP7809056B2 - 血液障害を処置するための組成物及び方法 - Google Patents

血液障害を処置するための組成物及び方法

Info

Publication number
JP7809056B2
JP7809056B2 JP2022522586A JP2022522586A JP7809056B2 JP 7809056 B2 JP7809056 B2 JP 7809056B2 JP 2022522586 A JP2022522586 A JP 2022522586A JP 2022522586 A JP2022522586 A JP 2022522586A JP 7809056 B2 JP7809056 B2 JP 7809056B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
hvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022522586A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551751A (ja
JP2022551751A5 (enExample
Inventor
イェドノック，テッド
サンカラナラヤナン，セテュ
Original Assignee
アネクソン，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アネクソン，インコーポレーテッド filed Critical アネクソン，インコーポレーテッド
Publication of JP2022551751A publication Critical patent/JP2022551751A/ja
Publication of JP2022551751A5 publication Critical patent/JP2022551751A5/ja
Priority to JP2025171716A priority Critical patent/JP2026028257A/ja
Application granted granted Critical
Publication of JP7809056B2 publication Critical patent/JP7809056B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022522586A 2019-10-17 2020-10-16 血液障害を処置するための組成物及び方法 Active JP7809056B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025171716A JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962916492P 2019-10-17 2019-10-17
US62/916,492 2019-10-17
PCT/US2020/056121 WO2021076991A1 (en) 2019-10-17 2020-10-16 Compositions and methods for treating blood disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025171716A Division JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Publications (3)

Publication Number Publication Date
JP2022551751A JP2022551751A (ja) 2022-12-13
JP2022551751A5 JP2022551751A5 (enExample) 2023-10-24
JP7809056B2 true JP7809056B2 (ja) 2026-01-30

Family

ID=75538375

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022522586A Active JP7809056B2 (ja) 2019-10-17 2020-10-16 血液障害を処置するための組成物及び方法
JP2025171716A Pending JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025171716A Pending JP2026028257A (ja) 2019-10-17 2025-10-10 血液障害を処置するための組成物及び方法

Country Status (11)

Country Link
US (1) US20240109957A1 (enExample)
EP (1) EP4045084A4 (enExample)
JP (2) JP7809056B2 (enExample)
KR (1) KR20220083737A (enExample)
CN (1) CN114746118A (enExample)
AU (1) AU2020365132A1 (enExample)
BR (1) BR112022007051A2 (enExample)
CA (1) CA3157873A1 (enExample)
IL (1) IL292186A (enExample)
MX (1) MX2022004287A (enExample)
WO (1) WO2021076991A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
AU2021361067A1 (en) * 2020-10-16 2023-06-01 Annexon, Inc. Compositions and methods for treating blood disorders
US12486322B2 (en) * 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN118259018B (zh) * 2024-03-21 2024-10-29 泰州市人民医院 C1s抗体制备及其在ITP诊断中的应用
CN119371528B (zh) * 2024-10-30 2025-06-24 泰州市人民医院 一种C1q抗体及其应用、一种抑制补体经典途径活化的药剂及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160159890A1 (en) 2013-07-09 2016-06-09 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
US20170152309A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
JP2018501813A (ja) 2014-11-05 2018-01-25 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077483A1 (en) * 2007-12-14 2009-06-25 Novo Nordisk A/S Antibodies against human nkg2d and uses thereof
CN106349390B (zh) * 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
PT2861246T (pt) * 2012-06-18 2021-04-05 Univ Leicester Composições e métodos para inibir masp-1 e/ou masp-2 e/ou masp-3 para o tratamento de várias doenças e perturbações
CN104231085B (zh) * 2013-09-05 2017-03-15 复旦大学附属肿瘤医院 靶向特异性补体系统抑制剂、其制备方法及应用
US9382321B2 (en) * 2014-11-26 2016-07-05 Adventis Health System/Sunbelt, Inc. Effector-deficient anti-CD32A antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160159890A1 (en) 2013-07-09 2016-06-09 Annexon, Inc. Methods of treatment for alzheimer's disease and huntington's disease
JP2016526393A (ja) 2013-07-09 2016-09-05 アネクソン，インコーポレーテッド 抗補体因子Ｃ１ｑ抗体及びその使用
JP2018501813A (ja) 2014-11-05 2018-01-25 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
US20170152309A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof
WO2017091719A1 (en) 2015-11-24 2017-06-01 Annexon, Inc. Anti-complement factor c1q fab fragments and uses thereof

Also Published As

Publication number Publication date
MX2022004287A (es) 2022-07-19
CA3157873A1 (en) 2021-04-22
JP2022551751A (ja) 2022-12-13
AU2020365132A1 (en) 2022-04-28
EP4045084A4 (en) 2023-05-31
KR20220083737A (ko) 2022-06-20
EP4045084A1 (en) 2022-08-24
WO2021076991A1 (en) 2021-04-22
US20240109957A1 (en) 2024-04-04
JP2026028257A (ja) 2026-02-19
CN114746118A (zh) 2022-07-12
IL292186A (en) 2022-06-01
BR112022007051A2 (pt) 2022-07-05

Similar Documents

Publication Publication Date Title
JP2026028257A (ja) 血液障害を処置するための組成物及び方法
JP7499760B2 (ja) 脳損傷を治療するための組成物及び方法
KR102626877B1 (ko) 인간화 항-보체 인자 c1q 항체 및 이의 용도
SA111320266B1 (ar) أجسام مضادة مع ارتباط مولد مضاد يعتمد على الأس الهيدروجيني
KR20190005944A (ko) 척수성 근위축 치료용 조성물 및 방법
CN108779171A (zh) 抗补体因子c1q的fab片段及其应用
CA3030872A1 (en) Compositions and methods for treating frontotemporal dementia
KR20230117192A (ko) 안구 질환을 치료하기 위한 조성물 및 방법
JP2024503724A (ja) 免疫調節抗体およびその使用
US20230391858A1 (en) Compositions and methods for treating blood disorders
CN115996752B (zh) 用于治疗癫痫的组合物和方法
JP2024539141A (ja) 筋ジストロフィーを治療するための組成物及び方法
US20260139047A1 (en) Pharmaceutical composition containing fusion protein
JP2025515485A (ja) 眼の疾患を治療するための組成物及び方法
HK40077291A (en) Compositions and methods for treating blood disorders
RU2786053C2 (ru) Фармацевтическая композиция для применения для лечения или предупреждения с5-связанного заболевания и способ лечения или предупреждения с5-связанного заболевания

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220609

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251010

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260106

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260120

R150 Certificate of patent or registration of utility model

Ref document number: 7809056

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150